DNTH

Dianthus Therapeutics, Inc.

Insider Trades

ActorHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Randhawa SimratEVP, Head Of R&D
$740k8.2k shares
SellJun 1, 2026
$1.5M16.9k shares
$90.72
--
Randhawa SimratEVP, Head Of R&D
$2.3M25.1k shares
SellJun 1, 2026
$487.0K5.4k shares
$89.72
--
Randhawa SimratEVP, Head Of R&D
$365k4k shares
SellJun 1, 2026
$380.0K4.2k shares
$91.37
--
Randhawa SimratEVP, Head Of R&D
$674k30.5k shares
Grant / ExerciseJun 1, 2026
$206.9K9.4k shares
$22.07
--
Randhawa SimratEVP, Head Of R&D
$461k21.2k shares
Grant / ExerciseJun 1, 2026
$136.0K6.2k shares
$21.77
--
Randhawa SimratEVP, Head Of R&D
$267k14.9k shares
Grant / ExerciseJun 1, 2026
$123.5K6.9k shares
$17.88
--

News

globenewswire.comDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 2seekingalpha.comDianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Winseekingalpha.comMay 30globenewswire.comDianthus Therapeutics to Participate in Two Investor Conferencesglobenewswire.comMay 26globenewswire.comOorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseasesglobenewswire.comMay 19fool.comDianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullishfool.comMay 18